We evaluated the effects of chitosan intake on fecal excretion of bisphenol A (BPA) and di(2-ethyl)phthalate (DEHP) in rats. The rats were fed a chitosan diet (CHI group) or a control diet (control group) for 10 d and orally administrated BPA or DEHP (100, 500 mg/kg body weight, respectively) on day 4. Feces were collected and the rates of fecal excretion of BPA and DEHP were calculated. Fecal excretion rates of BPA and DEHP were significantly higher in the CHI group than in the control group. A significant negative correlation was observed between the fecal excretion rates of BPA and DEHP and apparent fat digestibility. Furthermore, the CHI group showed not only increased but also accelerated BPA excretion into the feces. In conclusion, we found that that chitosan intake significantly increased the fecal excretion of BPA, DEHP, and fat, suggesting that it might be useful for reducing adverse effects caused by lipophilic xenobiotics.
Many environmentally harmful substances, including endocrine disrupting chemicals (EDCs), adversely affect living beings. EDCs include chemicals that are known for high accumulation in living organisms, including polychlorinated biphenyls, dichlorodiphenyltrichloroethane, and other pesticides, and chemicals that can potentially be absorbed by living organisms, including bisphenol A (BPA), used in the manufacture of resins, nonylphenol, used as a surfactant, and phthalate esters, used as plasticizers.
BPA, a highly lipophilic chemical and one of the most widely produced EDCs, is used in manufacturing polycarbonate plastics and epoxy resins, 1, 2) used in the packaging of foods and beverages. Di (2-ethylhexyl) phthalate (DEHP) is a highly lipophilic phthalate ester used to providing flexibility to polyvinyl plastic. It has been reported that reproductive dysfunction can be influenced by exposure to EDCs, which show many physiological effects, including diabetes, liver enzyme gamma-glutamyltransferase and alkaline phosphatase abnormalities, stronger immune responses following BPA exposure, 3, 4) and decreased urinary excretion of vitamins 5) after DEHP exposure. Hence, the physiological effects of EDCs ought to be investigated.
Chitosan (-poly-D-glucosamine, CHI) is an aminopolysaccharide derived from chitin, found in the exoskeletons of arthropods. Although not derived from plants, it is similar to a dietary fiber, as it is indigestible by human digestive enzymes. 6) Many studies have been conducted to evaluate the effects of chitosan on fat metabolism, and it has been reported that it decreases blood cholesterol levels [7] [8] [9] [10] [11] and liver cholesterol levels in rats, 7, 8, 12) reduces cholesterol absorption in rats, 12) increases bile acid and fat excretion in rats, 12) and reduces fat digestibility in the ileum of broiler chickens. 10, 11) We have also found that chitosan enhances fecal fat excretion in rats fed a diet containing chitosan (Kohda et al., unpublished data).
In this study, we evaluated the effects of chitosan on the fecal excretion of highly lipophilic chemicals such as BPA or DEHP orally administered to rats in a single dose.
Materials and Methods
Animal and diets. Study 1: Twenty 4-week-old male SpragueDawley rats were purchased from CLEA Japan (Tokyo). After 7 d of quarantine, the rats were divided into 2 groups by random sampling and stratified on the basis of body weight (BW): (i) The control group was administered 100 mg/kg BW of BPA and fed the control diet (the BPA-control group, n ¼ 10), and (ii) the chitosan group was administered 100 mg/kg BW of BPA and fed a diet containing 5% chitosan (the BPA-CHI group, n ¼ 10).
Study 2: Twenty 4-week-old male Sprague-Dawley rats were purchased from CLEA Japan. After 7 d of quarantine, the rats were divided into 2 groups by random sampling and stratified on the basis of body weight: (i) The control group was administered 500 mg/kg BW of DEHP and fed the control diet (the DEHP-control group, n ¼ 10), and (ii) the chitosan group was administered 500 mg/kg BW of DEHP and fed a diet containing 5% chitosan (the DEHP-CHI group, n ¼ 10).
The rats were housed individually in metal cages at a temperature of 24 C AE 1 C and a humidity of 55 AE 10% under a light-dark cycle (light period, 0700-1900; dark period, 1900-0700). During quarantine for 7 d, the rats were fed a purified diet (AIN-93G) ad libitum. Table 1 shows the composition of the diet. The viscosity and degree of deacetylation of chitosan were 105 mPaÁs and 89.1% (Koyo Chemical, Osaka, Japan). A portion of the cornstarch in the purified diet was replaced with chitosan.
After randomizing to the various groups, the rats were transferred to stainless steel metabolic cages, the BPA-CHI and DEHP-CHI groups were freely fed a diet containing 5% chitosan, and the BPA-control and DEHP-control groups were freely fed the AIN-93G diet for 10 d. On the 4th day, the rats were orally administered a single dose of BPA or DEHP dissolved in soybean oil (100 mg BPA/mL of soybean oil/kg BW, 500 mg DEHP/mL of soybean oil/kg BW) at 0900.
Body weight and diet consumption were measured daily at the time of feeding. After completion of the study, the rats were exsanguinated under ether anesthesia. Feces were collected in aluminum foil bags to avoid contamination, and fecal wet weight was measured at 0900 daily. The feces were freeze-dried for 3 d. Fecal dry weight was measured, and fecal fat and fecal BPA or DEHP levels were analyzed using ground feces. All animal procedures were approved by the Ethics Committee for Animal Experiments of Otsuka Pharmaceuticals Co., Ltd.
Gas chromatography-mass spectrometry analysis of fecal BPA and DEHP. BPA analyses were performed on days 1, 2, 3, and 4 to 7, and DEHP analyses were performed on days 1 to 7. Gas chromatographymass spectrometry (GC-MS) analysis was carried out using a GC-MS QP-5050A instrument (Shimadzu, Kyoto, Japan) equipped with a DB-1701 (15 m Â 0:25 mm internal diameter, 0.25 mm film thickness, J & W, Agilent Technologies, Santa Clara, CA) for BPA, and using a GC-MS QP-5050 (GC-17) instrument (Shimadzu) equipped with a DB-5 (30 m Â 0:25 mm internal diameter, 0.25 mm film thickness, J & W, Agilent Technologies, Santa Clara, CA) for DEHP. BPA and DEHP were analyzed at Shimadzu Techno-Research, following to the assay methods of the Ministry of the Environment of Japan, 13, 14) and the values were corrected by BPA-d16 and DEHP-d4 respectively. The amount of fecal BPA (or DEHP) excretion was calculated by the following formula: an amount of fecal BPA (or DEHP) excretion ¼ fecal BPA (or DEHP) concentration Â fecal dry weight. The fecal BPA (or DEHP) excretion rate was calculated by the following formula: fecal BPA (or DEHP) excretion rate (%) ¼ amount of fecal BPA (or DEHP) excretion/amount of BPA (or DEHP) ingestion Â 100.
Fecal fat analysis. Fecal samples were collected for 2 d before BPA or DEHP administration, and fecal fats were analyzed by the Folch method. 15) Apparent fat digestibility was calculated by the following formula: apparent fat digestibility (%) ¼ (weight of consumed fat À weight of fat excreted in feces)/weight of consumed fat Â 100.
Statistical analyses.
Results are shown as mean AE SD. SAS Release 8.1 was used for statistical analysis. Student's t test was performed to compare control and chitosan groups. Correlations between the rates of fecal BPA and apparent fat digestibility and the rate of DEHP excretion and apparent fat digestibility were analyzed by the Spearman rank method. The level of significance was set at p ¼ 0:05.
Results

Effects of chitosan intake on body weight gain and food intake
Weight gain, total diet consumption, and feed efficiency are shown in Table 2 . There were no significant differences in weight gain, total diet consumption, or feed efficiency between the BPA-CHI and the BPA-control group. In contrast, although there were no significant differences in weight gain or total diet consumption between the DEHP-CHI and the DEHPcontrol group, feed efficiency significantly decreased in the DEHP-CHI group.
Effects of chitosan intake on fecal weight and fecal fat excretion
Fecal wet and dry weights and fecal water content rates are shown in Table 3 . Fecal wet and dry weights were significantly higher in the BPA-CHI group than in the BPA-control group. For DEHP, fecal wet and dry weights were significantly higher in the DEHP-CHI group than in the DEHP-control group, but no significant difference was observed in fecal water contents.
As shown in Table 3 , fecal fat excretion was significantly higher and apparent fat digestibility was significantly lower in the BPA-CHI group than in the BPA-control group (p < 0:01 for both). Similarly, in DEHP, fecal fat excretion was significantly higher and apparent fat digestibility was significantly lower in the DEHP-CHI group than in the DEHP-control group (p < 0:01 for both).
Effects of chitosan intake on fecal excretion of BPA and DEHP Figure 1 and Table 4 show the 7-d fecal excretion rates of BPA and DEHP and the absolute fecal excretion of BPA and DEHP. Fecal excretion rates of BPA and DEHP were significantly higher in the CHI groups than in the control groups (p < 0:01 for both). Absolute fecal excretion of BPA and DEHP was significantly higher than in either control group on days 1, 2, 1-3, and 1-7 in the BPA group and on days 1-7 in the DEHP group.
The correlation between the rate of fecal BPA excretion and apparent fat digestibility is shown in Fig. 2 . Figure 3 shows correlations between the rate of fecal DEHP excretion and apparent fat digestibility. Apparent fat digestibility was lower in both groups fed chitosan, which showed high excretion rates of BPA and DEHP, and significant negative correlations were observed between the rate of fecal excretion and apparent fat digestibility (BPA: r ¼ 0:8278, p < 0:01, DEHP: r ¼ 0:6444, p < 0:05).
For BPA, which showed a high correlation between the rate of fecal excretion and apparent fat digestibility, fecal BPA excretion rates were analyzed temporally (Fig. 4) . The BPA-CHI group showed significantly higher values at days 1, 2, and over the first 3 d than the BPA-control group (p < 0:01 for all 3 d). In the BPA-CHI group, BPA was excreted via the feces at the rates of 73.9% and 76.1% within 3 d and 7 d respectively. After BPA administration, fecal BPA excretion peaked at days 1 and 2 for the BPA-CHI group, followed by a rapid decrease, while no peak was observed for the 
Fig. 1. Effects of Chitosan on Fecal Excretion of BPA and DEHP.
Rats were fed the control diet or 5% chitosan diet during the experimental period. At day 4 (0 d after BPA or DEHP administration), they were administered BPA (100 mg/kg BW) or DEHP (500 mg/kg BW). After BPA or DEHP administration, feces were collected over 7 d. Values are presented as mean AE SD (n ¼ 10). Significant difference vs. control as determined by Student's t test. ÃÃ p < 0:01. Rats were fed the control diet or the 5% chitosan diet during the experimental period. Fecal samples were collected for 2 d before administration of BPA. Fecal fats were analyzed, and apparent fat digestibility was calculated. After BPA administration, fecal samples were collected over 7 d. BPA excretion in the feces over 7 d was analyzed, and fecal BPA excretion rates were calculated. r ¼ 0:8278, p < 0:01. Significant correlation determined by Spearman correlation coefficient. Rats were fed the control diet or the 5% chitosan diet during the experimental period. Fecal samples were collected over 2 d before the administration of DEHP. Fecal fats were analyzed, and apparent fat digestibility was calculated. After DEHP administration, fecal samples were collected over 7 d. DEHP excretion into the feces over 7 d was analyzed, and fecal DEHP excretion rates were calculated. r ¼ 0:6444, p < 0:05. Significant correlation determined by Spearman correlation coefficient.
BPA-control group. For days 4 to 7, fecal BPA excretion was significantly higher in the BPA-control group than in the BPA-CHI group, in contrast to the first 3 d.
Discussion
The accumulation of BPA and DEHP in living organisms is not well understood. Because the effects of exposure to these chemicals is not fully understood yet, it is important not only to reduce exposure but also to evaluate the process by which they are excreted. BPA and DEHP are lipophilic chemicals that might have physiological effects. When orally administered, their absorption kinetics are similar to those of fat. We confirmed that chitosan reduces apparent fat digestibility. Furthermore, we confirmed that chitosan is an effective food ingredient inducing dioxin excretion in orally administered rats (Kohda et al., unpublished results). To test the hypothesis that chitosan enhances the fecal excretion of lipophilic EDCs, we evaluated the effects of chitosan on fecal excretion of BPA and DEHP, which were orally administered in a single dose.
BPA is absorbed from the gastrointestinal tract, metabolized into glucuronate conjugate and sulfoconjugate by drug-metabolizing enzymes, and excreted into the urine or feces. The glucuronate conjugate excreted via bile becomes lipophilic when deconjugated by bacteria in the colon, and is reabsorbed from the gastrointestinal tract into the liver. The BPA that is not reabsorbed is excreted into the feces. 16) Knaak et al. reported that 28% and 56% of a single dose of 14 C-BPA (800 mg/kg BW) orally administered to male rats was excreted through the urine (as glucuronate conjugate) and the feces (about 20% free BPA, about 20% hydroxylated BPA, and about 16% unknown) respectively. 17) A total of 80% of the dose was excreted in the urine and feces at day 2, and only very little radioactivity was observed in the rats at day 8. 17) Pottenger et al. reported that 81:8 AE 5:98% and 14:15 AE 1:99% of a single dose of 14 C-BPA (100 mg/kg BW) orally administered to male rats was excreted through the feces and the urine (96:59 AE 5:89% in total) respectively over 7 d. 18) Moreover, Yoo et al. reported that the absolute oral bioavailability of BPA was low (5:3 AE 2:1%). 19) Because most of BPA is excreted through the feces, we evaluated the fecal excretion rates of BPA and DEHP to examine directly the excretion of orally administered BPA. We also investigated the function of chitosan, which has the ability to induce the excretion of fat and lipophilic chemicals.
In our study, the rate of fecal excretion of BPA (100 mg/kg BW) administered to the control group for 7 d was 29:7 AE 9:5% (Fig. 1) , similar to the fecal excretion level of free BPA reported by Knaak et al.
(about 20%, 14 C-BPA 800 mg/kg BW). 17) The rate of fecal excretion of BPA in the BPA-CHI group was significantly higher than in the BPA-control group at days 1 and 2 and the first 3 d and 7 d. Since the total excretion rate of BPA and BPA metabolites did not change significantly on days 3 to 8, 17) the rates on the following days were thought to be low. It was, therefore, speculated that the total excretion rates for 7 d were nearly equal to the true total excretion rate. We found that dietary intake of 5% chitosan significantly increased total fecal excretion of orally administered BPA and facilitated excretion over time. Since dietary intake of 5% chitosan facilitates fecal BPA excretion over time and increases the total fecal excretion rate of BPA more efficiently than the intake of the control diet did under present study conditions, intake of chitosan can enhance the fecal excretion of lipophilic EDCs, including orally administered BPA.
BPA absorption influences the body in various ways. Probiotics have been reported to increase fecal BPA excretion. Probiotic intake groups have shown lower blood BPA concentrations than control groups. 20) We did not evaluate blood BPA concentration. However, the effect of chitosan intake in increasing fecal BPA excretion over 7 d was approximately the same as that of probiotic intake (chitosan, 2.6 times; probiotics, 2.4-2.5 times), and chitosan intake increased fecal BPA excretion, particularly during the first 2 d. Therefore, similarly to the effect seen for probiotics, chitosan intake might prevent increases in the blood BPA concentration.
DEHP is hydrolyzed by intestinal function to mono(2-ethylhexyl)phthalate (MEHP) and 2-ethylhexanol, 21) absorbed from the gastrointestinal tract, and metabolized. 22) Most DEHP that is neither hydrolyzed nor absorbed is excreted in the feces as unchanged DEHP. 23) Because orally administered DEHP does not circulate enterohepatically as unchanged DEHP, previously absorbed and metabolized DEHP might not affect the fecal excretion of DEHP, and approximately 80% of DEHP is excreted into the feces and urine 5 to 7 d after oral administration. 23) Hence, we analyzed the feces collected for 7 d and measured the excretion of unchanged DEHP only in the feces.
In our study, the rate of fecal DEHP excretion for 7 d in the DEHP-control group was 33:5 AE 7:3% (Fig. 1) Rats were fed the control diet or the 5% chitosan diet during the experimental period. The fecal BPA excretion rate was analyzed temporally. After BPA administration, feces were collected over 7 d. In the BPA-CHI group, most of the BPA was excreted in the feces within 3 d after administration. Excreted BPA increased significantly over in the BPA-control group. Values are presented as mean AE SD (n ¼ 10). Significant difference vs. control as determined by Student's t test.
ÃÃ p < 0:01.
DEHP-CHI group, the fecal DEHP excretion rate was significantly higher than in the DEHP-control group. These results suggest that intake of chitosan increases not only the excretion rate of BPA but also that of DEHP. Furthermore, we confirmed that intake of chitosan increases the excretion rate of dioxins in rats (Kohda et al., unpublished results). Thus intake of chitosan might promote the excretion of other lipophilic EDCs.
Significant negative correlations between the rates of fecal BPA and apparent fat digestibility and the rate of DEHP excretion and apparent fat digestibility (BPA: p < 0:01, DEHP: p < 0:05) were observed, indicating that fecal fat excretion affects fecal BPA and DEHP excretion. Because BPA and DEHP are lipophilic EDCs, it is thought that they are absorbed into the body through incorporation into lipid micelles. Furthermore, it has been reported that chitosan can inhibit pancreatic lipase activity. 25) In this study, therefore, the effect of chitosan intake in promoting fecal fat and fecal lipophilic EDC excretion is thought to have been due to the inhibition of absorption of them by chitosan, inhibiting pancreatic lipase activity and fat absorption.
Intake of dietary fiber affects the absorption of PCBs and lipophilic EDCs such as BPA and DEHP. [26] [27] [28] [29] [30] Previous reports have suggested that the mechanism promoting fecal PCB excretion through the intake of chitosan, rice bran, and wheat bran includes the following: (i) PCB is adsorbed into poorly fermented dietary fiber, enhancing fecal PCB elimination, and (ii) gastrointestinal transit is influenced by fiber content. Therefore, poorly fermented fiber sources that reduce resident time, such as chitosan, should lower the in vivo absorption of environmental contaminants. In contrast, it has been reported that chitosan can inhibit pancreatic lipase activity, 25) and there was a significant negative correlation between rates of fecal EDCs and apparent fat digestibility in our study. Based on these factors, the mechanism of chitosan's effect in promoting fecal EDC excretion might include inhibition of fat absorption and of the EDCs dissolved in fat.
In conclusion, we found that dietary intake of chitosan significantly increases the fecal excretion of BPA and DEHP. Chitosan is thought to affect fecal fat excretion, suggesting that it might be useful for reducing the adverse effects of lipophilic xenobiotic substances. Further studies are necessary to determine the effects of chitosan intake in humans.
